Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures: 2021-2025

Historic Capital Expenditures for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to $597,000.

  • Kiniksa Pharmaceuticals International's Capital Expenditures rose 2495.65% to $597,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 293.39%. This contributed to the annual value of $277,000 for FY2024, which is 113.08% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Capital Expenditures stood at $597,000 for Q3 2025, which was up 149.79% from $239,000 recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Capital Expenditures' 5-year high stood at $597,000 during Q3 2025, with a 5-year trough of -$32,000 in Q4 2022.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Capital Expenditures averaged around $122,000, with its median value being $76,000 (2024).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Capital Expenditures plummeted by 112.75% in 2022, and later surged by 2,495.65% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Capital Expenditures stood at $251,000 in 2021, then slumped by 112.75% to -$32,000 in 2022, then soared by 275.00% to $56,000 in 2023, then skyrocketed by 35.71% to $76,000 in 2024, then surged by 2,495.65% to $597,000 in 2025.
  • Its last three reported values are $597,000 in Q3 2025, $239,000 for Q2 2025, and $99,000 during Q1 2025.